611 related articles for article (PubMed ID: 19252424)
1. Protective effects of natural rotavirus infection.
Velázquez FR
Pediatr Infect Dis J; 2009 Mar; 28(3 Suppl):S54-6. PubMed ID: 19252424
[TBL] [Abstract][Full Text] [Related]
2. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
[TBL] [Abstract][Full Text] [Related]
3. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis.
Heaton PM; Goveia MG; Miller JM; Offit P; Clark HF
J Infect Dis; 2005 Sep; 192 Suppl 1():S17-21. PubMed ID: 16088800
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of an ideal rotavirus vaccine.
Reisinger KS; Block SL
Clin Pediatr (Phila); 2008 Jul; 47(6):555-63. PubMed ID: 18467670
[TBL] [Abstract][Full Text] [Related]
5. Discovery of rotavirus: Implications for child health.
Bishop R
J Gastroenterol Hepatol; 2009 Oct; 24 Suppl 3():S81-5. PubMed ID: 19799704
[TBL] [Abstract][Full Text] [Related]
6. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.
Chandran A; Santosham M
Expert Rev Vaccines; 2008 Dec; 7(10):1475-80. PubMed ID: 19053204
[TBL] [Abstract][Full Text] [Related]
7. Natural immunity to rotavirus infection in children.
Malik J; Bhan MK; Ray P
Indian J Biochem Biophys; 2008 Aug; 45(4):219-28. PubMed ID: 18788471
[TBL] [Abstract][Full Text] [Related]
8. Rotavirus serotypes: classification and importance in epidemiology, immunity, and vaccine development.
Hoshino Y; Kapikian AZ
J Health Popul Nutr; 2000 Jun; 18(1):5-14. PubMed ID: 11014764
[TBL] [Abstract][Full Text] [Related]
9. Influence of potential protective mechanisms on the development of live rotavirus vaccines.
Ward RL; Clark HF; Offit PA
J Infect Dis; 2010 Sep; 202 Suppl():S72-9. PubMed ID: 20684721
[TBL] [Abstract][Full Text] [Related]
10. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants.
Ruiz-Palacios GM; Guerrero ML; Bautista-Márquez A; Ortega-Gallegos H; Tuz-Dzib F; Reyes-González L; Rosales-Pedraza G; Martínez-López J; Castañón-Acosta E; Cervantes Y; Costa-Clemens S; DeVos B
Pediatrics; 2007 Aug; 120(2):e253-61. PubMed ID: 17606534
[TBL] [Abstract][Full Text] [Related]
11. Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, west Africa.
Fischer TK; Valentiner-Branth P; Steinsland H; Perch M; Santos G; Aaby P; Mølbak K; Sommerfelt H
J Infect Dis; 2002 Sep; 186(5):593-7. PubMed ID: 12195345
[TBL] [Abstract][Full Text] [Related]
12. Rotavirus vaccines: recent developments and future considerations.
Angel J; Franco MA; Greenberg HB
Nat Rev Microbiol; 2007 Jul; 5(7):529-39. PubMed ID: 17571094
[TBL] [Abstract][Full Text] [Related]
13. Immunity and correlates of protection for rotavirus vaccines.
Franco MA; Angel J; Greenberg HB
Vaccine; 2006 Apr; 24(15):2718-31. PubMed ID: 16446014
[TBL] [Abstract][Full Text] [Related]
14. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine.
Santos N; Hoshino Y
Rev Med Virol; 2005; 15(1):29-56. PubMed ID: 15484186
[TBL] [Abstract][Full Text] [Related]
15. Serotypes and subgroups of rotavirus isolated from children in central Brazil.
Cardoso das D; Soares CM; Azevedo MS; Leite JP; Munford V; Rácz ML
J Health Popul Nutr; 2000 Jun; 18(1):39-43. PubMed ID: 11014769
[TBL] [Abstract][Full Text] [Related]
16. Live attenuated human rotavirus vaccine, Rotarix.
Bernstein DI
Semin Pediatr Infect Dis; 2006 Oct; 17(4):188-94. PubMed ID: 17055369
[TBL] [Abstract][Full Text] [Related]
17. Rotavirus surveillance--worldwide, 2001-2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Nov; 57(46):1255-7. PubMed ID: 19023263
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil.
Correia JB; Patel MM; Nakagomi O; Montenegro FM; Germano EM; Correia NB; Cuevas LE; Parashar UD; Cunliffe NA; Nakagomi T
J Infect Dis; 2010 Feb; 201(3):363-9. PubMed ID: 20047501
[TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.
Clark HF; Bernstein DI; Dennehy PH; Offit P; Pichichero M; Treanor J; Ward RL; Krah DL; Shaw A; Dallas MJ; Laura D; Eiden JJ; Ivanoff N; Kaplan KM; Heaton P
J Pediatr; 2004 Feb; 144(2):184-90. PubMed ID: 14760258
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
Block SL; Vesikari T; Goveia MG; Rivers SB; Adeyi BA; Dallas MJ; Bauder J; Boslego JW; Heaton PM;
Pediatrics; 2007 Jan; 119(1):11-8. PubMed ID: 17200266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
